Skip to main content
SpringerLink
Log in
Book cover

Prehypertension and Cardiometabolic Syndrome pp 57–66Cite as

Prehypertension and the Cardiometabolic Syndrome

  • Chapter
  • First Online:

  • 688 Accesses

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

Abstract

Approaches to DASH eating plan and increased engagement in physical activity have shown to effectively lower BP and thus are recommended as the first choice for prehypertension management.

Individuals with BP in the upper range of prehypertension (130–139/85–89 mmHg) have a significantly higher risk for cardiovascular disease (CVD).

Pharmacological antihypertensive treatment, specifically trials assessing renin-angiotensin system blockers, has also demonstrated good efficacy and safety.

Numerous studies have shown the relative risk of progression to incident hypertension can be reduced by 20% with intensive lifestyle interventions and by 34–66% with single antihypertensive drug treatment.

More recent research has focused on early detection of additional risk factors among them serum C3 and serum uric acid that may serve as biomarkers in high-risk individuals to improve primary prevention of prehypertension and prediabetes.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–71.

    Article  CAS  PubMed  Google Scholar 

  2. Mancia G. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.

    Article  CAS  PubMed  Google Scholar 

  3. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682–6.

    Article  CAS  PubMed  Google Scholar 

  4. Shen L, Ma H, Xiang M-X, Wang J-A. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol. 2013;112(2):266–71.

    Article  PubMed  Google Scholar 

  5. Vasan RS, Larson MG, Leip EP, Evans JC, O’donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291–7.

    Article  CAS  PubMed  Google Scholar 

  6. Wang S, Wu H, Zhang Q, Xu J, Fan Y. Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168(5):4857–60.

    Article  PubMed  Google Scholar 

  7. McInnes G. Pre-hypertension: how low to go and do drugs have a role? Br J Clin Pharmacol. 2012;73(2):187–93.

    Article  PubMed  PubMed Central  Google Scholar 

  8. De Marco M, De Simone G, Roman MJ, Chinali M, Lee ET, Russell M, et al. Cardiovascular and metabolic predictors of progression of prehypertension into hypertension. Hypertension. 2009;54(5):974–80.

    Article  PubMed  CAS  Google Scholar 

  9. Chobanian AV. Prehypertension revisited. Hypertension. 2006;48:812–4.

    Article  CAS  PubMed  Google Scholar 

  10. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157(6):657–67.

    Google Scholar 

  11. Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein AC, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50(4):609–16.

    Article  CAS  PubMed  Google Scholar 

  12. Crist LA, Champagne CM, Corsino L, Lien LF, Zhang G, Young DR. Influence of change in aerobic fitness and weight on prevalence of metabolic syndrome. Prev Chronic Dis. 2012;9:E68.

    PubMed  PubMed Central  Google Scholar 

  13. Faselis C, Doumas M, Kokkinos JP, Panagiotakos D, Kheirbek R, Sheriff HM, et al. Exercise capacity and progression from prehypertension to hypertension novelty and significance. Hypertension. 2012;60(2):333–8.

    Article  CAS  PubMed  Google Scholar 

  14. Beck DT, Martin JS, Casey DP, Braith RW. Exercise training improves endothelial function in resistance arteries of young prehypertensives. J Hum Hypertens. 2014;28(5):303–9.

    Article  CAS  PubMed  Google Scholar 

  15. Beck DT, Martin JS, Casey DP, Braith RW. Exercise training reduces peripheral arterial stiffness and myocardial oxygen demand in young prehypertensive subjects. Am J Hypertens. 2013;26(9):1093–102.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Egan BM, Stevens-Fabry S. Prehypertension—prevalence, health risks, and management strategies. Nat Rev Cardiol. 2015;12(5):289–300.

    Article  PubMed  Google Scholar 

  17. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568):1208–19.

    Article  CAS  PubMed  Google Scholar 

  18. Segura J, Ruilope LM. Treatment of prehypertension in diabetes and metabolic syndrome. Diabetes Care. 2009;32(Suppl 2):S284–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure—a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7):1487–96.

    Article  PubMed  CAS  Google Scholar 

  20. Julius S, Nesbitt S, Egan B, Kaciroti N, Schork MA, Grozinski M, et al. Trial of preventing hypertension. Hypertension. 2004;44(2):146–51.

    Article  CAS  PubMed  Google Scholar 

  21. Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL, Trial of Preventing Hypertension (TROPHY) Investigators. TROPHY study: outcomes based on the seventh report of the joint National Committee on hypertension definition of hypertension. J Am Soc Hypertens. 2008;2(1):39–43.

    Article  PubMed  Google Scholar 

  22. Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, et al. An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the trial of preventing hypertension (TROPHY). J Clin Hypertens. 2008;10(6):436–42.

    Article  Google Scholar 

  23. Yao W, Sun Y, Wang X, Si Q, Chen H, Wan Z. High prevalence of metabolic syndrome in a middle-aged and elderly population with prehypertension in Tianjin. Clin Exp Hypertens. 2015;37(5):369–74.

    Article  CAS  PubMed  Google Scholar 

  24. Okada R, Yasuda Y, Tsushita K, Wakai K, Hamajima N, Matsuo S. The number of metabolic syndrome components is a good risk indicator for both early-and late-stage kidney damage. Nutr Metab Cardiovasc Dis. 2014;24(3):277–85.

    Article  CAS  PubMed  Google Scholar 

  25. Cordero A, Laclaustra M, León M, Grima A, Casasnovas JA, Luengo E, et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment: a Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens. 2006;19(2):189–96.

    Article  CAS  PubMed  Google Scholar 

  26. Hwu C-M, Liou T-L, Hsiao L-C, Lin M-W. Prehypertension is associated with insulin resistance. QJM. 2009;102(10):705–11.

    Article  CAS  PubMed  Google Scholar 

  27. Sathiyapriya V, Nandeesha H, Bobby Z, Pavithran P, Selvaraj N, Rattina DN. Insulin resistance and enhanced protein glycation in men with prehypertension. Clin Chem Lab Med. 2006;44(12):1457–61.

    Article  CAS  PubMed  Google Scholar 

  28. Natali A, Muscelli E, Casolaro A, Nilsson P, Melander O, Lalic N, et al. Metabolic characteristics of prehypertension: role of classification criteria and gender. J Hypertens. 2009;27(12):2394–402.

    Article  CAS  PubMed  Google Scholar 

  29. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJP. Cardiovascular metabolic syndrome--an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007;9(3):218–32.

    Article  CAS  PubMed  Google Scholar 

  30. Duprez D, Toleuova A. Prehypertension and the cardiometabolic syndrome: pathological and clinical consequences. Expert Rev Cardiovasc Ther. 2013;11(12):1725–33.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample. Hypertension. 2006;47(3):410–4.

    Article  CAS  PubMed  Google Scholar 

  32. Kim NH, Cho HJ, Kim YJ, Cho MJ, Choi HY, Eun CR, et al. Combined effect of high-normal blood pressure and low HDL cholesterol on mortality in an elderly Korean population: the South-West Seoul (SWS) study. Am J Hypertens. 2011;24(8):918.

    Article  PubMed  Google Scholar 

  33. Pletcher MJ, Bibbins-Domingo K, Lewis CE, Wei GS, Sidney S, Carr JJ, et al. Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med. 2008;149(2):91–9.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Diehl KJ, Weil BR, Greiner JJ, Wright KP, Stauffer BL, DeSouza CA. Impaired endogenous fibrinolytic capacity in prehypertensive men. J Hum Hypertens. 2015;29(8):468–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Hrafnkelsdóttir T, Wall U, Jern C, Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet. 1998;352(9140):1597–8.

    Article  PubMed  Google Scholar 

  36. Van Guilder GP. It is time to contend with the endothelial consequences of prehypertension. J Hum Hypertens. 2015;29(8):457.

    Article  PubMed  CAS  Google Scholar 

  37. Patil SG, Aithala M, Das KK. Evaluation of arterial stiffness in elderly with prehypertension. Indian J Physiol Pharmacol. 2015;59(1):16–22.

    Google Scholar 

  38. Tomiyama H, Yamashina A. Arterial stiffness in prehypertension: a possible vicious cycle. J Cardiovasc Transl Res. 2012;5(3):280–6.

    Article  PubMed  Google Scholar 

  39. Celik T, Yuksel UC, Fici F, Celik M, Yaman H, Kilic S, et al. Vascular inflammation and aortic stiffness relate to early left ventricular diastolic dysfunction in prehypertension. Blood Press. 2013;22(2):94–100.

    Article  CAS  PubMed  Google Scholar 

  40. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens. 2004;17(7):568–73.

    Article  CAS  PubMed  Google Scholar 

  41. Julius S, Egan BM, Kaciroti NA, Nesbitt SD, Chen AK, TROPHY Investigators. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension. J Hypertens. 2014;32(2):251–9.

    Article  CAS  PubMed  Google Scholar 

  42. Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412(13):1171–9.

    Article  CAS  PubMed  Google Scholar 

  43. Bao X, Xia Y, Zhang Q, Wu HM, Du HM, Liu L, et al. Elevated serum complement C3 levels are related to the development of prediabetes in an adult population: the Tianjin Chronic Low-Grade Systematic Inflammation and Health Cohort Study. Diabet Med. 2016;33(4):446–53.

    Article  CAS  PubMed  Google Scholar 

  44. Bao X, Meng G, Zhang Q, Liu L, Wu H, Du H, et al. Elevated serum complement C3 levels are associated with prehypertension in an adult population. Clin Exp Hypertens. 2017;39(1):42–9.

    Article  CAS  PubMed  Google Scholar 

  45. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739–42.

    Article  PubMed  Google Scholar 

  46. Saladini F, Mos L, Fania C, Garavelli G, Casiglia E, Palatini P. Regular physical activity prevents development of hypertension in young people with hyperuricemia. J Hypertens. 2017;35(5):994–1001.

    Article  CAS  PubMed  Google Scholar 

  47. Lotufo PA, Baena CP, Santos IS, Bensenor IM. Serum uric acid and prehypertension among adults free of cardiovascular diseases and diabetes: baseline of the Brazilian longitudinal study of adult health (ELSA-Brasil). Angiology. 2016;67(2):180–6.

    Article  CAS  PubMed  Google Scholar 

  48. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007;25(8):1583–9.

    Article  CAS  PubMed  Google Scholar 

  49. Jiang M, Gong D, Fan Y. Serum uric acid levels and risk of prehypertension: a meta-analysis. Clin Chem Lab Med. 2017;55(3):314–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology and Pharmacology, Tel-Aviv University, Sackler School of Medicine, Tel Aviv, Israel

    Talma Rosenthal

Authors
  1. Talma Rosenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Talma Rosenthal .

Editor information

Editors and Affiliations

  1. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Reuven Zimlichman

  2. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

    Stevo Julius

  3. Emeritus Professor of Medicine, University of Milano-Bicocca, Milan, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rosenthal, T. (2019). Prehypertension and the Cardiometabolic Syndrome. In: Zimlichman, R., Julius, S., Mancia, G. (eds) Prehypertension and Cardiometabolic Syndrome. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-319-75310-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-75310-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-75309-6

  • Online ISBN: 978-3-319-75310-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation